U.S. Markets closed

ARIAD price target lowered to $23 from $27 at Jefferies

Jefferies lowered its price target for ARIAD after the company's Iclusig drug won FDA approval with a boxed warning on previously undisclosed safety issues. However, Jefferies says it’s hard to know whether the issues are due to Iclusig or the underlying disease. The firm keeps a Buy rating on the stock